IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97, AND §1.98

PTO-1449 FORM (MODIFIED)

SHEET 1 OF 1

	ATTORNEY DOCKET NO. PP20426.003	SERIAL NO. 10/814,480
	APPLICANTS: Nicholas M. Valiante	EXAMINER: Yong Soo
	FILING DATE: March 29, 2004	
CONFIRMATION NO.		GROUP ART UNIT:
	9427	1617

Evido Hal	Ref No		Date	Name	Class	Subclass	Filed
YC	A1	6,211,177	3 April 2001	Speri et al.	ंदे तरक्षकाद्रस्य द	िर्वस्थानस्य व्यवस्थानस्य	North Halle
1	A2	6,248,771	19 June 2001	Shenoy et al.			
	A3	6,399,603	4 June 2002	Jacobs et al.			
1/	A4	6,417,194	9 July 2002	Fox et al.			

er Lipia i egus, ja		- i but	FOREIGN PATENT DO	CUMENTS				
Ex'r I nitial	Ref. No.	Document No. ::	Publication Date	Country	Class	Subclass	Tren	slation NO
YC	B1	WO 00/62778 A	26 October 2000	PCT				
i	B2	WO 01/66539 A	13 September 2001	PCT				
	В3	W004/985425A1	7 October 2004	PCT			. ,	
	B4	W002/42273A2	30 May 2002	PCT				
	B5	W002/44156A2	6 June 2002	PCT				
	В6	W002/076960A1	3 October 2002	PCT				
	В7	W002/094808A1	28 November 2002	PCT				
Ų.	88	W003/082272A1	9 October 2003	PCT	lin			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)						
Ex'r n itial	Ref. No.	Description .				
YC	C1					
	C2					
	C3					
₩	C4					

EXAMINER'S SIGNATURE Yorn Chory	DATE CONSIDERED

t EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered.

Include copy of this form in next communication to applicant.

If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to
the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R.
1.98(d).

SHEET	1	OF	1

FORM PTO-1449 (Medified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 20426.003	Serial No.: 10/814,480
INFORMATION DISCL	OSURE CITATION	Applicants: Valiante et al.	
(Use several s	theets if necessary)	Filing Date: March 29, 2004	Group: 1617

U.S. PATENT DOCUMENTS

*Examiner		Document Number	Date	Name	Class	Subclass	Piling Date
Initial		boculient Number	Date	Name	Ciass	Subclass	If Appropriate
YL	AA	2002/0107392	08/08/02	Renhowe et al.	544	60	09/11/01
	 		<u> </u>				
	 						
	 		 			<u> </u>	
	1				4		

FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans- Yes	lation No
YC	BA	WO 92/18483	10/29/92	PCT				
1	BB	WO 03/074515 A1	09/12/03	PCT				
	ВС	WO 03/082272	10/09/03	PCT				
	BD	WO 2004/018419 A2	03/04/04	PCT				
V	BE	WO 2004/085425 A1	10/07/04	PCT ·				
	1							

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER CITATIONS (Including Author, little, Date, Feltiment Pages, Etc.)						
YC.	CA	Ukrainets et al., "4-Hydroxy-2-Quinolones. 32. Synthesis and Antithyroid Activity of Thio Analogs of 1H-2-Oxo-3-(2-Benzimidazolyl)-4-Hydroxyquinoline* Chemistry of Heterocyclic Compounds 33(5):600-604, 1997					
Yc.	СВ	Ukrainets et al., "4-Hydroxy-2-Quinolones 7 Synthesis and Biological Properties of 1-R-3-(2-Benzimidazolyl)-4-Hydroxy-2-Quinolones" Chemistry of Heterocyclic Compounds 29(1):92-94, 1993					
		·					
ļ							
 							
ļ	-						

Examiner Vory Chong	Date Considered (0/20/05	
o jong com		

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<u> </u>			
FOR4 PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 20426.003	Serial No.: 10/814,480
INFORMATION DISCL	OSURE CITATION	Applicants: Valiante et al.	
(Use several s	heets if necessary)	Filing Date: March 29, 2004	Group: to be assigned

U.S. PATENT DOCUMENTS									
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate		
YL	AA	2002/0022624	02/21/02	Dinnell et al.					
	-								
	1 32 4								
	 		 						

		Document Number	Publ. Date	Country	Class	Subclass	Trans- Yes	lation No
YC	BA	WO 00/12074	03/09/00	PCT				
	ВВ	WO 02/22598	03/21/02	PCT				
	вс	WO 00/76505	12/21/00	PCT				
	BD	WO 01/64668	09/07/01	PCT			(abstract only)	
	BE .	WO 02/090375	05/02/01	PCT				
	BP	WO 02/083624	10/24/02	PCT				
	BG	WO 03/000694	01/03/03	PCT				
V	ВН	WO 00/59904	10/12/00	PCT				

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) Sato et al., "Characteristics of Antitumor Activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl)- . . ." Cancer Letters 91:1-9, 1995 AA YC Oyaizu et al., "Inhibition of CD4 Cross-Linking-Induced Lymphoyetes Apoptosis by Vesnarinone as a Novel Immunomodulating Agent . . . Blood 87(6):2361-2368, March 15, 1996 AC Toldy et al., "3,4,5-Trimethoxybenzoylderivative, Eine Neue Verbindungsgruppe Mit Antiulzerogener Wirkung" Acta Chimica Academiae Scientiarum Hungaricae Tomus 49(3):265-286, 1966 Sato et al., "Induction of Tumour Differentiation and Apoptosis and Le 7 Antigen Expression in Treatment with Differentiation-Inducing Agent, Vesnarinone, of a Patient with Salivary Adenoid Cystic Carcinoma" Apoptosis 2:106-113, 1997 AD Petigara <u>et al</u>., "Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives" <u>11</u>:332-336, March 1, 1968 AE Yamaguchi, "Vesnarinone Inhibits Growth of Large Cell Lung Cancer Cell Lines via Induction of Apoptosis" $\underline{\text{Med. }}\underline{\text{J. }}\underline{\text{Kagoshima}}\underline{\text{Univ. }}\underline{\text{51}(4):67-75, Pebruary, 2000}$ Examiner Date Considered 10/20/05 long (hong

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.